Novo Nordisk

We are a global healthcare company focused on driving change to defeat serious chronic diseases. General Information and Guidelines:

Novo Nordisk Inc.

(NNI) uses social media as part of our commitment to communicate with you in a transparent and timely manner. NNI offers several social media channels you can use to stay updated on company news and activities. We welcome your participation in our community if you exercise respective discourse and follow our guidelines below. When you engage with NNI on Facebook (and any other of NNI’s social medi

a channels), you are agreeing to these Community Guidelines in addition to the Terms and Conditions or other legal notices provided by NNI and those of Facebook: https://www.novonordisk-us.com/social-media-community-guidelines.html. If you have any questions about a NNI therapy or medicine, please contact our customer care line at 1-800-727-6500 or report your issue online at: https://www.novonordisk-us.com/contact-us.html.

06/19/2026

Some realities are hard to see.

Sickle cell disease is more than moments of pain. For millions of people around the world, it's a lifelong condition that shapes everyday decisions, future plans and the moments many of us take for granted.

This World Sickle Cell Disease Day, we're inviting people to look at sickle cell disease differently and consider what living with it really means.

Learn more about sickle cell disease: https://bit.ly/4xzBA4o

06/16/2026

Nearly 3 out of 4 of American adults are living with excess weight or obesity, but that burden is not shared equally.
Black and Hispanic communities face disproportionately higher rates of obesity in the US, influenced by biology, environment, and circumstance. It is a complex disease, and no one should have to face it alone.
The right support starts with understanding your personal risk factors, partnering with a healthcare professional you trust, and finding a community that has your back. Read more: https://bit.ly/4uZcJVn

06/07/2026

Our FDA-approved GLP-1 weight loss medicine has already surpassed three million prescriptions in the US since its launch — making it one of the strongest US pharmaceutical launches by volume on record.

Since its launch, prescriptions have been filled at roughly one every five seconds. We believe that every person deserves options that work for them, and we’re proud to be helping those who need it.

To us, this milestone represents millions of conversations about weight and health — and why access to care matters.

Read more here: https://bit.ly/4xfpfSE

06/06/2026

At , we're sharing new analyses that explore the impact of our FDA-approved weight loss medicine in other cardiometabolic conditions.

Learn more: https://bit.ly/4xdlvkE

06/04/2026

The GLP-1 hormone has become widely recognized for its role in metabolic health – but it is only one part of the story. At , we’ll be presenting data from our investigational amylin-based therapies.

Learn more about what’s new from Novo Nordisk at ADA: https://bit.ly/4e35THA

06/01/2026

New data shows 1 in 2 adults in the US with ASCVD and CKD show evidence of cardiovascular (CV) inflammation (defined as hsCRP ≥2 mg/L), even while on standard treatments for their heart disease. Novo Nordisk’s POSEIDON study presented at , highlights this critical gap in CV risk management.

Read more: https://bit.ly/4nYqH81

05/18/2026

When needs are met with purpose, futures are built.

As part of our work with Brownsville Community Culinary Center (BCCC) and Sodexo USA, we're helping connect Brownsville residents to healthy food, culinary training, and real career opportunities — from Brooklyn all the way to our U.S. headquarters.

This work is rooted in something simple: community-led solutions create lasting change. Better health outcomes don't happen without access, education, and trust — and we're honored to help build all three. 💙

Learn more: https://bit.ly/4tGkY7K

05/04/2026

We asked our community what they find most helpful during doctor’s appointments.

49% of people said judgement free discussions.
35% of people said knowing what to ask.

These results highlight the importance of supportive, informed conversations — especially when discussing weight and health.

Learn more: https://bit.ly/3OCEioj

05/01/2026

Now under one of America’s most recognizable brand names, our type 2 diabetes medicine offers another important option for patients and healthcare professionals.

Work with your healthcare professional to review your options, consider your individual needs, and select the treatment approach that’s right for you.

Learn more: https://bit.ly/42GqRH7

04/29/2026

Novo Nordisk started The Interrupt to help transform community well-being by bringing together corporate expertise and resources to tackle the social determinants of health—supporting the physical, mental, and social factors that help people thrive.

We are also honored to receive the Social Impact Changemaker Innovation Award from Boston College Center for Corporate Citizenship, recognizing the power of collaborative, place-based community partnerships. We share this honor with our partners Live HealthSmart Alabama and D.C.’s View Strong, whose work—ranging from refurbishing neighborhood parks and sidewalks to bringing food access and wellness programming—is strengthening communities at the local level.

Learn more about how we're supporting communities: https://bit.ly/4cPVsrT

Address

800 Scudders Mill Road
Plainsboro, NJ

Website

http://novonordisk.us/

Alerts

Be the first to know and let us send you an email when Novo Nordisk posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Engineering Company in Plainsboro?